Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Clovis Oncology, Inc.CLVS · Entity 122635 | Director | July 12, 2021 | July 13, 2021 |
| Gamida Cell Ltd.GMDA · Entity 94655 | CMO & CHIEF SCIENTIFIC OFFICER | January 31, 2024 | February 02, 2024 |
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Director | January 27, 2026 | January 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Clovis Oncology, Inc.
Report date July 12, 2021 · Filed July 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.30 · Expires 2031-07-12 | Direct | 83,212 |
Reported balance
After 2021-07-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-12 · Grant · Acquired 83,212 · Balance 83,212 F1: One-third (1/3) of the shares subject to the option shall vest on each of the first three (3) annual anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third (1/3) of the shares subject to the option shall vest on each of the first three (3) annual anniversaries of the date of grant.
Gamida Cell Ltd.
Report date January 31, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 655,896 |
Reported balance
After 2024-01-31 transaction · row 1
1 source rowRow 1 · 2024-01-31 · Grant · Acquired 480,319 · Balance 655,896 F1: Represents a restricted share unit award, and shall vest with respect to 33% of the RSUs, on each of July 31, 2024 and July 31, 2025, respectively, and with respect to 34% of the RSUs, on July 31, 2026. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit award, and shall vest with respect to 33% of the RSUs, on each of July 31, 2024 and July 31, 2025, respectively, and with respect to 34% of the RSUs, on July 31, 2026. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date.
Tempest Therapeutics, Inc.
Report date January 27, 2026 · Filed January 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2036-01-26 | Direct | 1,230 |
Reported balance
After 2026-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-27 · Grant · Acquired 1,230 · Balance 1,230 F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2026 Filed Jan 28, 2026 16:30 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (right to buy) · Derivative | 1,230 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001871563-26-000002 · form4-01282026_040107.xml · derivative · entry 1 Simantov Ronit · CIK 0001871563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,230 Underlying: Common Stock · 1,230 shares Expires 2036-01-26 F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 18:05 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001415889-24-017010 · form4-06142024_060603.xml · derivative · entry 1 Simantov Ronit · CIK 0001871563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 16:40 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 480,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002321 · form4-02022024_090226.xml · nonDerivative · entry 1 Simantov Ronit · CIK 0001871563 · CMO & CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 655,896 F1 · shares: Represents a restricted share unit award, and shall vest with respect to 33% of the RSUs, on each of July 31, 2024 and July 31, 2025, respectively, and with respect to 34% of the RSUs, on July 31, 2026. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 16:46 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (right to buy) · Derivative | 8,200 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001209191-23-038440 · doc4.xml · derivative · entry 1 Simantov Ronit · CIK 0001871563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,200 Underlying: Common Stock · 8,200 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 19:59 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantEmployee Share Option (Right to Buy) · Derivative | 116,340 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-23-008566 · doc4.xml · derivative · entry 2 Simantov Ronit · CIK 0001871563 · CMO & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,340 Underlying: Ordinary Shares · 116,340 shares Expires 2033-02-07 F2 · derivative.exercise_date: 33% of the shares subject to the option award shall vest on each of August 8, 2023 and August 8, 2024, respectively, and 34% of the shares subject to the option award shall vest on August 8, 2025, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 19:59 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 58,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008566 · doc4.xml · nonDerivative · entry 1 Simantov Ronit · CIK 0001871563 · CMO & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,577 F1 · shares: Represents a restricted share unit award, and shall vest with respect to 33% of the RSUs, on each of August 8, 2023 and August 8, 2024, respectively, and with respect to 34% of the RSUs, on August 8, 2025. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 16:11 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001179110-22-003377 · edgar.xml · derivative · entry 1 Simantov Ronit · CIK 0001871563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2032-06-16 F1 · derivative.exercise_date: Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 19:05 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 6,635 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001179110-21-008097 · edgar.xml · derivative · entry 1 Simantov Ronit · CIK 0001871563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,635 Underlying: Common Stock · 6,635 shares Expires 2031-08-05 F1 · derivative.exercise_date: Vests over three (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. Read SEC document |
| July 12, 2021 Filed Jul 13, 2021 16:25 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 83,212 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0000899243-21-028209 · doc4.xml · derivative · entry 1 Simantov Ronit · CIK 0001871563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,212 Underlying: Common Stock · 83,212 shares Expires 2031-07-12 F1 · derivative.exercise_date: One-third (1/3) of the shares subject to the option shall vest on each of the first three (3) annual anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.